Role of nerve growth factor and its receptors in non-nervous cancer growth: Efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies antityrosine kinase receptor A and antinerve growth factor: An in-vitro and in-vivo study

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 929-941

  Rende, Mario ^a   Pistilli, Alessandra ^a   Stabile, Anna Maria ^a   Terenzi, Adelmo ^a   Cattaneo, Antonino ^b   Ugolini, Gabriele ^b   Sanna, Pietro ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Lay Line Genomics SpA   (Italy)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

AG879; Muscular sarcoma; Nerve growth factor; Neutralizing antibodies; p75; Tyrosine kinase receptor A

Indexed keywords

3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; COMPLEMENTARY DNA; LIPOSOME; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NEUROTROPHIN; NEUTRALIZING ANTIBODY; PROTEIN P75; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE A ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA TRANSFECTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LEIOMYOSARCOMA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; TUMOR VOLUME;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; FEMALE; HL-60 CELLS; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; NERVE GROWTH FACTOR; PROTEIN KINASE INHIBITORS; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 33748444390     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224459.13651.fd     Document Type: Article

References (50)

1. Barbacid M. Structural and functional properties of the TRK family of neurotrophin receptors. Ann N Y Acad Sci 1995; 766:442-458.
2. Ibanez CF. Neurotrophic factors: from structure-function studies to the signing effective therapeutics. Trends Biotech 2001; 13:217-227.
3. Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol 1995; 7:148-155.
4. Greene LA, Kaplan DR. Early events in neurotrophin signalling via Trk and p75 receptors. Curr Opin Neurobiol 1995; 5:579-587.
5. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000; 14:2919-2937.
6. Acheson A, Lindsay RM. Non target-derived roles of the neurotrophins. Philos Trans R Soc Lond B Biol Sci 1996; 351:417-422.
7. Davies AM, Wright EM. Neurotrophic factors: neurotrophin autocrine loops. Curr Biol 1995; 5:723-726.
8. Schecterson LC, Bothwell M. Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons. Neuron 1992; 9:449-463.
9. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169:107-114.
10. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267:1782-1787.
11. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242:933-935.
12. Ohmichi M, Pang L, Ribon V, Gazit A, Levitzki A, Saltiel AR. The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry 1993; 32:4650-4658.
13. Rende M, Brizi E, Conner J, Treves S, Censier K, Provenzano C, et al. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA. Int J Dev Neurosci 2000; 18:869-885.
14. Clary DO, Weskamp G, Austin LR, Reichardt LF. TrkA cross-linking mimics neuronal responses to nerve growth factor. Mol Biol Cell 1994; 5:549-563.
15. Conner JM, Varon S. Characterization of antibodies to nerve growth factor: assay-dependent variability in the cross-reactivity with other neurotrophins. J Neurosci Methods 1996; 65:93-99.
16. Cattaneo A, Rapposelli B, Calissano P. Three distinct types of monoclonal antibodies after long-term immunization of rats with mouse nerve growth factor. J. Neurochem 1988; 50:1003-1010.
17. Molnar M, Tongiorgi E, Avignone E, Gonfloni S, Ruberti F, Domenici L, et al. The effects of anti-nerve growth factor monoclonal antibodies on developing basal forebrain neurons are transient and reversible. Eur J Neurosci 1998; 10:3127-3140.
18. Cattaneo A, Capsoni S, Margotti E, Righi M, Kontsekova E, Pavlik P, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci 1999; 19:9687-9697.
19. Covaceuszach S, Cattaneo A, Lamba D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Proteins 2005; 58:717-727.
20. Ellis AG, Nice EC, Weinstock J, Levitzki A, Burgess AW, Webster LK. High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. J Chromatogr B Biomed Sci Appl 2001; 754:193-199.
21. Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 1999; 5:2205-2212.
22. Marchetti D, Aucoin R, Blust J, Murry B, Greiter-Wilke A. A p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J Cell Biochem 2004; 91:206-215.
23. Sigala S, Martocchia A, Missale C, Falaschi P, Spano P. Increased serum concentration of nerve growth factor in patients with microprolactinoma. Neuropeptides 2004; 38:21-24.
24. Eggert A, Sieverts H, Ikegaki N, Brodeur GM. p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. Med Pediatr Oncol 2000; 35:573-576.
25. Eggert A, Ikegaki N, Liu XG, Brodeur GM. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin Padiatr 2000; 212:200-205.
26. Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt VV, Sieverts H, et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005; 228:143-153.
27. Descamps S, Lebourhis X, Delehedde M, Boilly B, Hondermarck H. Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem 1998; 273:16659-16662.
28. Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B, et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 2001; 61:4337-4340.
29. Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 2001; 276:17864-17870.
30. Dolle L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H. Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 2004; 4:463-470.
31. Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 2004; 10:7335-7346.
32. Guate JL, Fernandez N, Lanzas JM, Escaf S, Vega JA. Expression of p75(LNGFR) and Trk neurotrophin receptors in normal and neoplastic human prostate. BJU Int 1999; 84:495-502.
33. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150-160.
34. Weeraratna AT, Arnold JT, George DJ, De Marzo A, Isaacs JT. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000; 45:140-148.
35. Miknyoczki SJ, Wan W, Chang H, Dobrzanski P, Ruggeri BA, Dionne CA, et al. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res 2002; 8:1924-1931.
36. Krygier S, Djakiew D. The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res 2001; 21:3749-3755.
37. Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M, Sher E, et al. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci U S A 1989; 95:5366-5371.
38. Khwaja F, Djakiew D. Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor. Mol Carcinog 2003; 36:153-160.
39. Tabassum A, Khwaja F, Djakiew D. The p75(NTR) tumor suppressor induces caspase-mediated apoptosis in bladder tumor cells. Int J Cancer 2003; 105:47-52.
40. Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003; 9:2248-2259.
41. Bold RJ, Ishizuka J, Rajaraman S, Perez-Polo JR, Townsend CM Jr, Thompson JC. Nerve growth factor as a mitogen for a pancreatic carcinoid cell line. J Neurochem 1995; 64:2622-2628.
42. Zhang Y, Dang C, Ma Q, Shimahara Y. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol Rep 2005; 14:161-171.
43. Zhu Z, Kleeff J, Kayed H, Wang L, Korc M, Buchler MW, et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog 2002; 35:138-147.
44. Paez Pereda M, Missale C, Grubler Y, Arzt E, Schaaf L, Stalla GK. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol 2000; 167:99-106.
45. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol 2002; 12:260-267.
46. Rosini P, De Chiara G, Lucibello M, Garaci E, Cozzolino F, Torcia M. NGF withdrawal induces apoptosis in CESS B cell line through p38 MAPK activation and Bcl-2 phosphorylation. Biochem Biophys Res Commun 2000; 278:753-759.
47. De Vries A, Engels F, Henricks PA, Leusink-Muis T, Fischer A, Nijkamp FP. Antibodies directed against nerve growth factor inhibit the acute bronchoconstriction due to allergen challenge in guinea-pigs. Clin Exp Allergy 2002; 32:325-328.
48. He H, Hirokawa Y, Manser E, Lim L, Levitzki A, Maruta H. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J 2001; 7:191-202.
49. Levi-Montalcini R, Hamburger V. A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in chick embryo. J Exp Zool 1953; 123:233-287.
50. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005; 65:9426-9435.